Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono Cetrotide

Executive Summary

Gonadotropin releasing hormone will be marketed, distributed and sold exclusively by Serono under a deal reached with Asta Medica. The two companies were scheduled to co-promote Cetrotide (cetrorelix) worldwide except for Japan. The NDA, approved Aug. 11, will now be transferred to Serono (1"The Pink Sheet" Aug. 21, p. 10)

You may also be interested in...



Asta Medica Cetrotide Approved For Single- And Multiple-Dose Regimens

Asta Medica's Cetrotide (cetrorelix) controlled ovarian stimulation injection received FDA approval for a 3 mg single-dose regimen and a .25 mg multiple-dose regimen on Aug. 11.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel